Summary of Incyte (INCY) FY Conference Call - June 09, 2025 Company Overview - **Company**: Incyte Corporation (INCY) - **Focus**: Oncology and other therapeutic areas with a strong emphasis on drug development and commercialization Key Points Commercial Portfolio and Revenue Growth - Incyte has expanded its commercial portfolio beyond Jakafi, with expected revenues of €650 million from ObsElura and over €400 million from oncology assets in 2025, totaling over $1 billion from products outside Jakafi this year [1][2] - Four product launches are anticipated, contributing an additional $1 billion by 2029, indicating a strong growth trajectory [2] Pipeline Developments - The company is in a pivotal year with four Phase III programs, with three readouts completed and one pending [3] - The POVO program for hidradenitis suppurativa (HS) is highlighted as significant, with positive Phase III data expected to drive future growth [3][4] Mutant KALAR Program Insights - Initial Phase I data for the mutant KALAR program shows good tolerability, with only one out of 40 patients discontinuing treatment [6][7] - The program aims to normalize platelet counts and reduce the malignant clone in patients with essential thrombocythemia (ET) [8][9] Jakafi Performance - Jakafi reported a strong Q1 with 24% year-over-year growth, driven by demand, net price adjustments, and reduced destocking [21] - The company raised its 2025 guidance to approximately 7% year-over-year growth at the midpoint, with future growth expected to be demand-driven [21][22] Opselura Sales Trajectory - Opselura is projected to generate $650 million in revenue for 2025, reflecting a 28% year-over-year growth, with contributions from both the U.S. and Europe [26] - The potential approval for pediatric atopic dermatitis (AD) is seen as a significant opportunity, targeting around 2 million children in the U.S. [28][32] POVO Commercial Strategy - Despite initial data falling short of expectations, Incyte emphasizes the positive outcomes from two Phase III trials for POVO, particularly in pain improvement for HS patients [38][39] - The company anticipates a substantial commercial opportunity with approximately 30,000 patients ready for POVO at launch [42] Pipeline Diversification - Incyte's pipeline includes a variety of therapeutic modalities, including bispecifics, traditional biologics, and small molecules, which helps mitigate risks across different therapeutic areas [46] Capital Allocation Strategy - The company prioritizes its internal pipeline and is unlikely to pursue major deals in the near term, focusing instead on early-stage technologies and near-commercial assets that can enhance revenue without significantly increasing R&D costs [54][56] Additional Insights - Compliance issues in vitiligo treatment have been addressed through educational initiatives to improve patient adherence to therapy [33][34] - The company is optimistic about the potential of its pipeline to redefine treatment approaches for various malignancies, particularly in myeloproliferative neoplasms [48][49] This summary encapsulates the key discussions and insights from Incyte's FY conference call, highlighting the company's growth strategies, pipeline developments, and market opportunities.

Core Viewpoint - Incyte's shares have increased by approximately 3.6% since the last earnings report, which is underperforming compared to the S&P 500 [1] Group 1: Earnings Report and Market Reaction - The recent earnings report is crucial for understanding the key drivers affecting Incyte's stock performance [1] - Estimates for Incyte have remained flat over the past month, indicating no significant changes in market expectations [2] Group 2: VGM Scores and Investment Strategy - Incyte has a strong Growth Score of A, a Momentum Score of B, and a Value Score of A, placing it in the top quintile for value investment strategy [3] - The overall aggregate VGM Score for Incyte is A, which is relevant for investors not focused on a single strategy [3] Group 3: Outlook - Incyte holds a Zacks Rank of 3 (Hold), suggesting an expectation of an in-line return from the stock in the upcoming months [4]

Core Viewpoint - Incyte's new drug Zynyz has received FDA approval for treating locally recurrent or metastatic squamous cell carcinoma of the anal canal, marking it as the first and only first-line treatment for advanced anal cancer in the United States [1][2]. Group 1: Drug Approval and Clinical Data - Zynyz is approved in combination with platinum-based chemotherapy for first-line treatment and as a monotherapy for patients intolerant to or whose disease progressed on platinum-based chemotherapy [1][2]. - The approval was based on data from two studies: the phase III POD1UM-303/InterAACT2 study and the phase II POD1UM-202 study [5]. - The POD1UM-303 study showed a 37% reduction in the risk of progression or death with Zynyz plus chemotherapy, while the POD1UM-202 study reported an objective response rate of 14% and a disease control rate of 49% for Zynyz monotherapy [6]. Group 2: Financial Impact and Market Position - Zynyz generated sales of $3 million in Q1 2025, and the approval is expected to enhance future sales [7]. - The approval diversifies Incyte's portfolio, reducing reliance on its lead drug Jakafi, which generated $709.4 million in Q1 2025, reflecting a 24% year-over-year increase [8]. Group 3: Competitive Landscape - Incyte currently holds a Zacks Rank of 3 (Hold), while competitors like Halozyme Therapeutics and Intellia Therapeutics have better rankings of 2 (Buy) [9].

Summary of Incyte (INCY) 2025 Conference Call Company Overview - **Company**: Incyte Corporation (INCY) - **Event**: Bank of America Healthcare Conference - **Date**: May 13, 2025 Key Industry Insights - **Impact of Executive Order**: The recent executive order lacks details, making it difficult to assess its impact on Incyte. The company primarily commercializes Jakafi in the U.S., with Novartis handling pricing outside the U.S. [3][4] - **Pipeline Flexibility**: Incyte's pipeline is not yet commercialized, allowing flexibility in response to potential pricing frameworks [5] - **Tariffs**: Expected to have minimal impact on Incyte as Jakafi is manufactured in the U.S. and the company employs a dual sourcing strategy [8][9] Financial Performance - **Jakafi Performance**: - Grew 24% year-over-year, with a 10% increase driven by demand and a 7% reduction in destocking [16] - The impact of the Part D redesign resulted in a smaller participation in the initial and catastrophic phases, benefiting the company [15] - **Opsilura Growth**: - Achieved 38% year-over-year growth, with projected net sales for the year between $630 million to $670 million [21][22] - The product is differentiated by rapid itch reduction for atopic dermatitis (AD) and is the only therapy available for vitiligo [22][32] Product Development and Pipeline - **Jakafi XR**: Expected to file for approval by the end of 2025, with anticipated approval in mid-2026. This product aims to transition existing patients to a once-a-day regimen before the patent expiry [18][19] - **Opsilura in Other Indications**: Plans to proceed with pivotal trials for Opsilura in mild to moderate hidradenitis suppurativa (HS) [35] - **POVO Development**: Two positive pivotal phase three trials conducted, with a focus on pain management in HS. Expected to file for approval by late 2026 or early 2027 [48][44] Market Position and Strategy - **Jakafi's Role**: Continues to generate significant cash flow, allowing for investment in new growth drivers. The goal is to not only replace Jakafi but to achieve double-digit growth post-Jakafi [20][59] - **Market Potential**: There are over five million patients with AD in the U.S., indicating significant room for growth. The company aims to penetrate this market further, especially among pediatric patients [29][28] - **Competitive Landscape**: Incyte believes it has the best topical treatment for itch improvement in AD, positioning itself favorably in a crowded market [32] Additional Considerations - **Patient Adherence**: Improvement in patient adherence is crucial for long-term revenue growth, particularly in vitiligo [25][26] - **Future Programs**: The mutant cholera antibody program is highlighted as a key focus for the next 15-20 years, aiming to dominate the myeloproliferative neoplasm space [50][52] This summary encapsulates the critical points discussed during the Incyte conference call, highlighting the company's current performance, strategic direction, and market opportunities.

Financial Performance - Syndax Pharmaceuticals reported $20.0 million in net revenue from Revuforj® (revumenib) in the first full quarter of its launch [1][4] - Niktimvo™ (axatilimab-csfr) generated $13.6 million in net revenue in its first partial quarter of launch, as reported by Incyte [1][8] - The company had cash, cash equivalents, and investments totaling $602.1 million as of March 31, 2025, which is expected to fund operations until profitability [1][7] Business Developments - The company submitted a supplemental New Drug Application (sNDA) for revumenib for the treatment of relapsed or refractory (R/R) mutant NPM1 acute myeloid leukemia (AML) [1][4] - A pivotal frontline trial of revumenib in combination with venetoclax and azacitidine for mNPM1 and KMT2Ar AML has been initiated [1][4] - Multiple ongoing trials are evaluating revumenib in various combinations and settings, including a Phase 1 trial showing a 100% overall response rate in newly diagnosed mNPM1 or KMT2Ar AML patients [4][5] Research and Development - Research and development expenses for the first quarter of 2025 increased to $61.6 million from $56.5 million in the prior year, driven by costs related to axatilimab and ongoing clinical trials [10] - Selling, general, and administrative expenses rose to $41.0 million from $23.0 million, primarily due to increased employee-related expenses and marketing efforts for Revuforj [11] - The company plans to initiate multiple trials of revumenib in combination with standard care regimens for newly diagnosed acute leukemia patients starting in the second half of 2025 [5][10] Future Outlook - For the second quarter of 2025, the company expects research and development expenses to be between $70 million and $75 million, with total operating expenses projected to be between $110 million and $115 million [13] - The company anticipates that its current cash position, along with expected product revenue, will enable it to reach profitability [14]

Core Viewpoint - The article discusses the emergence of Demy Pharmaceutical, a subsidiary of Kangzhe Pharmaceutical, focusing on the development and market potential of the drug "Ruxolitinib Cream" for treating vitiligo, amidst a growing demand for effective skin health products in China [1][2]. Company Overview - Demy Pharmaceutical is set to independently list in Hong Kong, having submitted its prospectus in April 2023, and is positioned to capitalize on the skin health market, which is projected to be worth billions [1][2]. - The company has a strong product pipeline, including Ruxolitinib Cream, which is the only FDA-approved JAK inhibitor for vitiligo, and other skin-related products [3][5]. Market Potential - There are over 10 million vitiligo patients in China, and the market for effective treatments is largely untapped, with Ruxolitinib Cream expected to generate significant revenue, projected at $340 million in its first full sales year [4][10]. - The skin health market is characterized by a high demand for unique and effective treatments, with Demy focusing on products that have a strong market need and limited competition [7][11]. Financial Performance - Demy Pharmaceutical has shown promising financials, with revenues expected to exceed 600 million yuan in 2024, reflecting a growth trend in the skin health segment [2][7]. - The company has maintained a positive cash flow despite not yet being profitable, indicating strong market interest and potential for future growth [2][10]. Product Pipeline - The product pipeline includes several other skin prescription drugs, with a focus on unique and differentiated products that address significant medical needs [5][7]. - The company has successfully introduced products that are the only approved treatments for specific conditions in China, enhancing its competitive edge [7][11]. Sales Strategy - Demy Pharmaceutical's sales strategy emphasizes leveraging its parent company's marketing expertise and established distribution channels, with a focus on hospital and retail pharmacy coverage [10][12]. - The company has a strong commercial team, with over 85% of its workforce dedicated to sales, which is crucial for its growth in the competitive biopharmaceutical market [10][12].

[Part I: Financial Information](index=3&type=section&id=PART%20I%3A%20FINANCIAL%20INFORMATION) [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) In Q1 2025, Incyte reported total revenues of $1.05 billion, net income of $158.2 million, and maintained a strong balance sheet with $2.4 billion in cash and marketable securities Summary of Financial Performance | Financial Metric | March 31, 2025 (in thousands) | March 31, 2024 (in thousands) | | :--- | :--- | :--- | | **Total Revenues** | $1,052,898 | $880,889 | | **Income from Operations** | $205,168 | $91,898 | | **Net Income** | $158,203 | $169,548 | | **Diluted EPS** | $0.80 | $0.75 | Summary of Balance Sheet | Balance Sheet Item | March 31, 2025 (in thousands) | December 31, 2024 (in thousands) | | :--- | :--- | :--- | | **Cash, Cash Equivalents & Marketable Securities** | $2,408,658 | $2,158,092 | | **Total Current Assets** | $3,507,421 | $3,239,030 | | **Total Assets** | $5,749,365 | $5,444,322 | | **Total Current Liabilities** | $1,720,290 | $1,641,847 | | **Total Liabilities** | $2,081,802 | $1,996,694 | | **Total Stockholders' Equity** | $3,667,563 | $3,447,628 | - Net cash provided by operating activities increased to **$266.1 million** for the three months ended March 31, 2025, compared to **$218.8 million** in the same period of 2024, primarily due to changes in working capital[19](index=19&type=chunk)[278](index=278&type=chunk) [Revenues Breakdown](index=9&type=section&id=Note%203.%20Revenues) Revenue Sources | Revenue Source (in thousands) | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | **Product Revenues, Net** | | | | JAKAFI | $709,412 | $571,839 | | OPZELURA | $118,705 | $85,724 | | ICLUSIG | $29,544 | $30,343 | | MINJUVI/MONJUVI | $29,551 | $23,874 | | NIKTIMVO | $13,613 | $0 | | **Total Product Revenues, Net** | **$922,274** | **$729,923** | | **Product Royalty Revenues** | | | | JAKAVI | $92,145 | $89,595 | | OLUMIANT | $30,800 | $30,589 | | **Total Product Royalty Revenues** | **$130,624** | **$125,966** | | **Milestone and Contract Revenues** | $0 | $25,000 | | **Total Revenues** | **$1,052,898** | **$880,889** | [Acquisitions](index=12&type=section&id=Note%206.%20Acquisitions) - In February 2024, Incyte acquired exclusive global rights to tafasitamab (MONJUVI/MINJUVI) from MorphoSys for a **$25.0 million** payment, terminating their previous collaboration agreement[44](index=44&type=chunk) - In May 2024, the company acquired Escient Pharmaceuticals, a clinical-stage drug development company, for **$782.5 million** in cash, accounted for as an asset acquisition with INCB000262 representing substantially all fair value[47](index=47&type=chunk)[48](index=48&type=chunk) [License Agreements](index=14&type=section&id=Note%208.%20License%20Agreements) - **Novartis:** Incyte receives tiered, double-digit royalties (upper-teens to mid-twenties) on JAKAVI net sales outside the U.S. and **12%-14%** on worldwide TABRECTA net sales, while paying Novartis low single-digit royalties on U.S. JAKAFI sales[54](index=54&type=chunk) - **Lilly:** Incyte is eligible for tiered, double-digit royalties up to the mid-twenties on global sales of OLUMIANT (baricitinib)[57](index=57&type=chunk) - **Syndax:** Incyte co-commercializes NIKTIMVO (axatilimab) in the U.S., sharing profits and losses equally, and has exclusive commercialization rights ex-U.S. with tiered royalties paid to Syndax[70](index=70&type=chunk) [Commitments and Contingencies](index=22&type=section&id=Note%2015.%20Commitments%20and%20Contingencies) - Incyte has accrued approximately **$145.4 million** for potential incremental rebates related to a lawsuit against CMS over OPZELURA's classification as a "line extension" of JAKAFI[103](index=103&type=chunk) - The company has an outstanding contractual dispute with Novartis regarding royalties allegedly owed on JAKAFI net sales within the United States, with a trial scheduled for May 2025[54](index=54&type=chunk)[104](index=104&type=chunk) - The company maintains a **$500.0 million** unsecured revolving credit facility, extended to June 2027, with no outstanding borrowings as of March 31, 2025[99](index=99&type=chunk)[100](index=100&type=chunk) [Management's Discussion and Analysis (MD&A)](index=25&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Q1 2025 financial performance was driven by strong revenue growth from JAKAFI and OPZELURA, with total revenues up 19.5% to $1.05 billion, supported by pipeline investments and a strong liquidity position [Overview of Business and Pipeline](index=30&type=section&id=Overview%20of%20Business%20and%20Pipeline) - Incyte is a global biopharmaceutical company focused on Hematology/Oncology and Inflammation and Autoimmunity (IAI), including its Dermatology franchise[122](index=122&type=chunk) - **Hematology/Oncology Pipeline Highlights:** sBLA submitted for Tafasitamab in FL, positive Phase 3 results for Retifanlimab in SCAC and NSCLC, and early clinical activity for INCB123667 (CDK2i) with a pivotal trial anticipated in 2025[148](index=148&type=chunk)[163](index=163&type=chunk)[178](index=178&type=chunk)[179](index=179&type=chunk) - **Inflammation & Autoimmunity (IAI) Pipeline Highlights:** Ruxolitinib cream (OPZELURA) Phase 3 met primary endpoint in pediatric atopic dermatitis, and Povorcitinib (oral JAK1) showed positive Phase 3 results in HS supporting planned regulatory submissions[198](index=198&type=chunk)[199](index=199&type=chunk)[206](index=206&type=chunk)[211](index=211&type=chunk) [Results of Operations](index=47&type=section&id=Results%20of%20Operations) Revenue Performance | Revenue Source (in millions) | Q1 2025 | Q1 2024 | % Change | | :--- | :--- | :--- | :--- | | JAKAFI revenues, net | $709.4 | $571.8 | +24.1% | | OPZELURA revenues, net | $118.7 | $85.7 | +38.5% | | Total product revenues, net | $922.3 | $729.9 | +26.4% | | Total product royalty revenues | $130.6 | $126.0 | +3.7% | | **Total revenues** | **$1,052.9** | **$880.9** | **+19.5%** | - JAKAFI revenue growth was driven by a **10% increase** in paid demand, the positive impact of the Part D redesign under the Inflation Reduction Act, and a **7% favorable impact** from less de-stocking compared to Q1 2024[254](index=254&type=chunk) - OPZELURA revenue growth was driven by a **24% increase** in U.S. prescription paid demand and **$23.5 million** in net product revenues from outside the U.S., primarily from Germany and France[255](index=255&type=chunk) Operating Expenses | Operating Expenses (in millions) | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Cost of product revenues | $73.2 | $61.0 | | Research and development | $437.3 | $429.3 | | Selling, general and administrative | $325.7 | $300.3 | [Liquidity and Capital Resources](index=52&type=section&id=Liquidity%20and%20Capital%20Resources) - As of March 31, 2025, the company had **$2.4 billion** in cash, cash equivalents, and marketable securities[277](index=277&type=chunk) Cash Flow Activity | Cash Flow Activity (in millions) | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $266.1 | $218.8 | | Net cash provided by (used in) investing activities | $1.1 | $(73.1) | | Net cash used in financing activities | $(12.7) | $(12.4) | - The company believes its cash flow from operations, existing cash balances, and available credit will be adequate to satisfy its capital needs for the foreseeable future[283](index=283&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=53&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company's market risks primarily involve interest rate fluctuations on its $466.9 million marketable securities portfolio and price volatility of strategic equity investments - The company's marketable securities of **$466.9 million**, primarily U.S. government debt, are subject to interest rate risk, but a **10% immediate rate increase** would not cause a material decline in fair value[285](index=285&type=chunk) - Strategic equity investments in publicly traded companies are subject to stock price volatility, which will cause fluctuations in reported gains and losses in future periods[286](index=286&type=chunk) [Controls and Procedures](index=53&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2025, with no material changes to internal control over financial reporting during the quarter - The Chief Executive Officer and Chief Financial Officer concluded that as of March 31, 2025, the company's disclosure controls and procedures were effective at the reasonable assurance level[288](index=288&type=chunk) - No changes occurred in the company's internal control over financial reporting during the quarter that materially affected, or are reasonably likely to materially affect, these controls[289](index=289&type=chunk) [Part II: Other Information](index=53&type=section&id=PART%20II%3A%20OTHER%20INFORMATION) [Risk Factors](index=53&type=section&id=Item%201A.%20Risk%20Factors) The company faces substantial risks including heavy reliance on JAKAFI/JAKAVI revenues, intense competition, generic challenges, pricing pressures, and inherent drug development uncertainties - **Product Concentration:** The business depends heavily on JAKAFI/JAKAVI, and any decrease in its revenues could materially harm the company[292](index=292&type=chunk) - **Competition and Generic Challenges:** The company faces competition from major pharmaceutical companies and potential generic products, with ANDAs filed challenging patents for JAKAFI (Apotex, Hikma) and OPZELURA (Padagis, Taro, Zydus)[320](index=320&type=chunk)[325](index=325&type=chunk) - **Pricing and Reimbursement:** Commercialization depends on adequate coverage and reimbursement from payors, with healthcare reform measures like the Inflation Reduction Act potentially impacting pricing and profitability[295](index=295&type=chunk)[339](index=339&type=chunk) - **Development and Regulatory Risk:** Drug discovery and development are expensive, uncertain, and time-consuming, with high risks of clinical trial failure and lengthy regulatory approval processes[329](index=329&type=chunk)[331](index=331&type=chunk) [Legal Proceedings](index=53&type=section&id=Item%201.%20Legal%20Proceedings) Legal proceedings, detailed in Note 15, include a lawsuit against CMS regarding OPZELURA classification and a contractual dispute with Novartis over JAKAFI royalties - Information regarding legal proceedings is incorporated by reference from Note 15 of the Condensed Consolidated Financial Statements[290](index=290&type=chunk) [Other Information](index=82&type=section&id=Item%205.%20Other%20Information) Thomas Tray, VP and Chief Accounting Officer, adopted a Rule 10b5-1 trading plan for the sale of up to 1,614 shares of common stock, effective until February 28, 2026 - On February 28, 2025, Thomas Tray, VP, Chief Accounting Officer, adopted a Rule 10b5-1 trading plan for the sale of up to **1,614 shares** of common stock[414](index=414&type=chunk)

Core Viewpoint - Incyte Corporation reported strong first-quarter 2025 results, with adjusted earnings and revenues exceeding expectations, driven by the performance of its lead drug Jakafi and the launch of Opzelura [1][3][4]. Financial Performance - Adjusted earnings per share for Q1 2025 were $1.16, surpassing the Zacks Consensus Estimate of $1.01 and up from 58 cents in the same quarter last year [1]. - Total revenues reached $1.05 billion, a 20% increase year over year, exceeding the Zacks Consensus Estimate of $1 billion [1]. - Jakafi generated revenues of $709.4 million, a 24% increase from the previous year, driven by a 10% rise in paid demand, and also beating the Zacks Consensus Estimate of $661.1 million [3]. - Opzelura cream sales were $118.7 million, up 38% year over year, although it fell short of the Zacks Consensus Estimate of $127 million [4]. - Newly approved Zynyz generated $3 million in sales, significantly up from the previous year and exceeding the Zacks Consensus Estimate of $1.9 million [5]. Product Performance - Iclusig net product revenues were $29.5 million, down 3% year over year but above the Zacks Consensus Estimate of $28.7 million [5]. - Pemazyre sales were $18.4 million, reflecting a 4% year-over-year increase but missing the Zacks Consensus Estimate of $21.6 million [5]. - Minjuvi revenues totaled $29.6 million, a 24% increase year over year, but below the Zacks Consensus Estimate of $33.4 million [6]. - Axatilimab-csfr (Niktimvo) recorded $13.6 million in sales following its launch in Q1 2025 [7]. Guidance and Future Outlook - The company raised its 2025 Jakafi revenue guidance to a range of $2.95-$3 billion, up from the previous range of $2.93-$2.98 billion [15]. - Opzelura net product revenues are expected to be between $630-$670 million in 2025 [15]. - Adjusted research and development expenses are projected to be in the range of $1.78-$1.81 billion, while adjusted selling, general and administrative expenses are expected to be between $1.16-$1.19 billion [16]. Cash Position - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $2.4 billion, an increase from $2.2 billion as of December 31, 2024 [13].

Financial Performance - Total revenues reached $1.053 billion, a 20% year-over-year increase[10, 44] - Product revenues amounted to $922 million, reflecting a 26% year-over-year growth[10, 44] - Jakafi net sales were $709 million, up 24% year-over-year, driven by strong patient demand[23, 46] - Opzelura net sales reached $119 million, a 38% year-over-year increase, fueled by U.S prescription growth and European launches[34, 48] - Niktimvo achieved $14 million in net sales during its initial U.S launch[36] Product & Pipeline Development - Jakafi's FY25 guidance raised to $2.95 - $3.0 billion[26] - Opzelura's FY25 guidance is $630 - $670 million[34] - Povorcitinib demonstrated positive Phase 2 results in CSU, with a planned discussion with the FDA to finalize Phase 3 design[15, 68] - The company anticipates having more than 10 high impact launches by 2030[5, 63] Financial Outlook - The company has $2.4 billion in cash[11] - GAAP Cost of product revenues is unchanged at 8.5 – 9% of net product revenues[60] - GAAP Research and development expenses is unchanged at $1.930 - $1.960 million[60]

Core Insights - Incyte reported $1.05 billion in revenue for Q1 2025, a 19.5% year-over-year increase, with an EPS of $1.16 compared to $0.64 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $1.01 billion by 4.66%, and the EPS also surpassed the consensus estimate of $1.01 by 14.85% [1] Revenue Performance - Net product revenues for Pemazyre were $18.44 million, below the average estimate of $21.62 million, representing a 4.3% year-over-year increase [4] - Total product revenues reached $922.27 million, exceeding the average estimate of $876.70 million, with a year-over-year change of 26.4% [4] - Iclusig generated $29.54 million in net product revenues, slightly above the average estimate of $28.67 million, but a 2.6% decrease year-over-year [4] - Minjuvi/Monjuvi reported $29.55 million, below the average estimate of $33.43 million, with a year-over-year increase of 23.8% [4] - Opzelura's net product revenues were $118.71 million, below the average estimate of $126.95 million, reflecting a 38.5% year-over-year increase [4] - Jakafi generated $709.41 million, surpassing the average estimate of $661.10 million, with a 24.1% year-over-year increase [4] - Zynyz reported $3.01 million, exceeding the average estimate of $1.92 million [4] Royalty Revenues - Jakavi's royalty revenues were $92.15 million, below the average estimate of $97.41 million, with a 2.9% year-over-year increase [4] - Total product royalty revenues reached $130.62 million, below the average estimate of $139.49 million, reflecting a 3.7% year-over-year increase [4] - Olumiant's royalty revenues were $30.80 million, below the average estimate of $34.90 million, with a 0.7% year-over-year change [4] - Tabrecta generated $6.41 million, exceeding the average estimate of $5.93 million, with a 22.5% year-over-year increase [4] Stock Performance - Incyte's shares returned -1.7% over the past month, compared to the S&P 500 composite's -0.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]